Related Experiment Video
Updated: Feb 5, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2
1PharmAbcine, Daejeon 305-811, Korea. biobuckeye@gmail.com
Abstract:
Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor growth and metastasis. Several anticancer therapies targeting VEGFR with small molecules and antibody have been currently studied in preclinical and clinical studies. This article provides a review of human monoclonal antibody tanibirumab (TTAC-0001), which specifically binds VEGFR-2 and is currently being developed in preclinical stage by PharmAbcine (Daejon, Korea).
Insights
This review covers tanibirumab, a human monoclonal antibody targeting vascular endothelial growth factor receptor-2 (VEGFR-2). It is being developed to inhibit angiogenesis, a key process in tumor growth and metastasis.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Vascular endothelial growth factor (VEGF) signaling drives tumor angiogenesis.
- VEGF receptor (VEGFR) inhibitors are a focus of cancer therapy.
- Angiogenesis is crucial for tumor growth and metastasis.
Purpose of the Study:
- To review the human monoclonal antibody tanibirumab (TTAC-0001).
- To highlight tanibirumab's specific binding to VEGFR-2.
- To discuss its preclinical development for cancer treatment.
Main Methods:
- Literature review of tanibirumab (TTAC-0001).
- Focus on its mechanism of action targeting VEGFR-2.
- Summary of preclinical development status.
Main Results:
- Tanibirumab is a human monoclonal antibody.
- It specifically targets and binds to VEGFR-2.
- The antibody is in the preclinical development stage.
Conclusions:
- Tanibirumab (TTAC-0001) shows potential as an anti-angiogenic cancer therapy.
- Targeting VEGFR-2 with monoclonal antibodies is a promising strategy.
- Further preclinical studies are essential for its development.
More Related Videos
Related Concept Videos
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
2° Amines to N-Nitrosamines: Reaction with NaNO2
SN2 Reaction: Kinetics
In a chemical reaction, a relationship exists between the concentration of reactants and the rate at which the reaction proceeds. The study to measure this relationship is known as the kinetics of a chemical reaction. Kinetic studies are used to deduce the rate law of a chemical reaction, which provides information about the species involved during the transition state of the rate-determining step. Thus, kinetic studies help to derive the mechanism of a...
SN2 Reaction: Mechanism
The presence of the more electronegative halogen in the substrate creates a polarized carbon-halide bond. The halide pulls the electron cloud generating an electrophilic center at the carbon atom. Thus, the carbon atom carries a partial positive charge while the halide has a...
SN2 Reaction: Transition State
When the nucleophile approaches the electrophilic carbon with its lone pairs, the halide acts as a leaving group and moves away with the electron-pair bonded to the carbon. Dotted partial bonds represent the bonds being formed or broken...
SN2 Reaction: Stereochemistry
If the substrate is an achiral molecule at the α-carbon, the inversion of configuration is not...

